# Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

> **NCT01638546** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 97 (actual)

## Conditions studied

- Recurrent Lung Small Cell Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **DRUG:** Temozolomide
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01638546
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-07-27
- **Primary completion:** 2017-01-09
- **Final completion:** 2027-03-25
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01638546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01638546, "Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01638546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*